Suppressive effect of clozapine but not haloperidol on the increases of neuropeptide-degrading enzymes and glial cells in MK-801-treated rat brain regions

Neuroscience Research

Volumn 57, Issue 2, 2007, Pages 248-258

  Arif, Mohammad ^a   Chikuma, Toshiyuki ^b   Ahmed, Md Mahiuddin ^a   Yoshida, Shunsuke ^a   Kato, Takeshi ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Glia; MK 801; Neuroleptics; Neuropeptidase; Schizophrenia like psychosis

Indexed keywords

ACETIC ACID; CD11B ANTIGEN; CLOZAPINE; DIMETHYL SULFOXIDE; DIZOCILPINE; GLIAL FIBRILLARY ACIDIC PROTEIN; HALOPERIDOL; NEUROLEPTIC AGENT; NEUROPEPTIDE; PROLYL ENDOPEPTIDASE; PROTEIN ANTIBODY; SODIUM CHLORIDE; THIMET OLIGOPEPTIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN CORTEX; BRAIN REGION; CINGULATE GYRUS; COGNITION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME REGULATION; FEMALE; IMMUNOHISTOCHEMISTRY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PSYCHOSIS; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; CLOZAPINE; DIZOCILPINE MALEATE; DRUG INTERACTIONS; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; HALOPERIDOL; METALLOENDOPEPTIDASES; NEUROGLIA; OLIGONUCLEOTIDES; RATS; RATS, WISTAR; SERINE ENDOPEPTIDASES;

EID: 33846589762     PISSN: 01680102     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neures.2006.10.021     Document Type: Article

References (48)

1. Ahmed M.M., Yamamoto M., Chikuma T., Rahman M.K., and Kato T. Dose-dependent effect of MK-801 on the levels of neuropeptides processing enzymes in rat brain regions. Neurosci. Res. 47 (2003) 177-189
2. Andine P., Widermark N., Axelsson R., Nyberg G., Olofsson U., Martensson E., and Sandberg M. Characterization of MK-801-induced behavior as a putative rat model of psychosis. J. Pharmacol. Exp. Ther. 290 (1999) 1393-1408
3. Arif M., Ahmed M.M., Kumabe Y., Hoshino H., Chikuma T., and Kato T. Clozapine but not haloperidol suppresses the changes in the levels of neuropeptides in MK-801-treated rat brain regions. Neurochem. Int. 49 (2006) 304-311
4. Ashby, and Wang R.Y. Pharmacological actions of the atypical antipsychotic drug clozapine: a review. Synapse 24 (1996) 349-394
5. Auer R.N. Effect of age and sex on N-methyl-d-aspartate antagonist-induced neuronal necrosis in rats. Stroke 27 (1996) 734-746
6. Bakshi V.P., Swerdlow N.R., and Geyer M.A. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J. Pharmacol. Exp. Ther. 271 (1994) 787-794
7. Bayer T.A., Buslei R., Havas L., and Falkai P. Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci. Lett. 271 (1999) 126-128
8. Crack P.J., Wu T.J., Cummins P.M., Ferro E.S., Tullai J.W., Glucksman M.J., and Roberts J.L. The association of metalloendopeptidase EC 3.4.24.15 at the extracellular surface of the AtT-20 cell plasma membrane. Brain Res. 835 (1999) 113-124
9. De Wied D., and Sigling H.O. Neuropeptides involved in the pathophysiology of schizophrenia and major depression. Neurotox. Res. 4 (2002) 453-468
10. Farber N.B., Foster J., Duhan N.L., and Olney J.W. Olanzapine and fluperlapine mimic clozapine in preventing MK-801 neurotoxicity. Schizophr. Res. 21 (1996) 33-37
11. Farber N.B., Kim S.H., Dikranian K., Jiang X.P., and Heinkel C. Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity. Mol. Psychiatry 7 (2002) 32-43
12. Fix A.S., Horn J.W., Wightman K.A., Johnson C.A., Long G.G., Storts R.W., Farbe N., Wozniak D.F., and Olney J.W. Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-D-aspartate (NMDA) antagonist MK (+) 801 (Dizocilpine maleate): A light and electron microscopic evaluation of the rat retrosplenial cortex. Exp. Neurol. 123 (1993) 204-215
13. Fujimura M., Hashimoto K., and Yamagami K. Effects of antipsychotic drugs on neurotoxicity, expression of fos-like protein and c-fos mRNA in the retrosplenial cortex after administration of dizocilpine. Eur. J. Pharmacol. 398 (2000) 1-10
14. Gaisler-Salomon I., and Weiner I. Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol. Psychopharmacology 166 (2003) 333-342
15. Gass P., Herdegen T., Bravo R., and Kiessling M. Induction and suppression of immediately early genes in specific rat brain regions by the non-competitive N-methyl-d-aspartate receptor antagonist MK-801. Neuroscience 53 (1993) 749-758
16. Gleason S.D., and Shannon H.E. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin subtype selective antagonists in mice. Psychopharmacology 129 (1997) 79-84
17. Hetman M., Danysz W., and Kaczmarek L. Increased expression of cathepsin d in retrosplenial cortex of MK-801-treated rats. Exp. Neurol. 147 (1997) 229-237
18. Horvath Z.C., Czopf J., and Buzsaki G. MK-801-induced neuronal damage in rats. Brain Res. 753 (1997) 181-195
19. Huston J.P., and Hasenohrl R.U. The role of neuropeptides in learning: focus on the neurokinin substance P. Behav. Brain Res. 66 (1995) 117-127
20. Iritani S. Peptidergic neuronal systems in schizophrenia. Recent Res. Dev. Neurochem. 4 (2001) 21-47
21. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148 (1991) 1301-1308
22. Kato T., Nakano T., Kojima K., Nagatsu T., and Sakakibara S. Changes in prolyl endopeptidase during maturation of rat brain and hydrolysis of substance P by the purified enzyme. J. Neurochem. 35 (1980) 527-535
23. Koshiya K., Kato T., Tanaka R., and Kato T. Brain peptidases: their possible neuronal and glial localization. Brain Res. 324 (1984) 261-270
24. Koshiya K., Okada M., Imai K., Kato T., Tanaka R., Hatanaka H., and Kato T. Localization of angiotensin-converting enzyme, prolyl endopeptidase and other peptidases in cultured neuronal or glial cells. Neurochem. Int. 7 (1985) 125-130
25. Loscher W., Annies R., and Honack D. Comparison of competitive and uncompetitive NMDA receptor antagonoists with regard to monoaminergic neuronal activity and behavioural effects in rats. Eur. J. Pharmacol. 242 (1993) 263-274
26. Maes M., Lin A.H., Bonaccorso S., Gooseens F., Van Gastel A., Pioli R., Delmeire L., and Scharpe S. Higher serum prolyl endopeptidase activity in patients with post-traumatic stress disorder. J. Affect. Disord. 53 (1999) 27-34
27. Malhotra A.K., Pinals D.A., Weingartner H., Sirocco K., Missar C.D., Pickar D., and Breier A. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14 (1996) 301-307
28. Martin P., Carlsson M.L., and Hjorth S. Systemic PCP treatment elevates brain extracellular 5-HT: a microdialysis study in awake rats. Neuroreport 9 (1998) 2985-2988
29. Massarelli E.E., Casatti C.A., Kato A., Camargo A.C.M., Bauer J.A., Glucksman M.J., Roberts J.L., Hirose S., and Ferro E.S. Differential subcellular distribution of neurolysin (EC 3.4.24.16) and thimet oligopeptidase (EC 3.4.24.15) in the rat brain. Brain Res. 851 (1999) 261-265
30. 2A receptors. Eur. J. Pharmacol. 280 (1995) R9-R11
31. Minoshima S., Giordani B., Berent S., Frey K.A., Foster N.L., and Kuhl D.E. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann. Neurol. 42 (1997) 85-94
32. Nakahara T., Kuroki T., Hondo H., Tsutsumi T., Fukuda K., Yao H., and Uchimura H. Effects of atypical antipsychotic drugs vs. haloperidol on expression of heat shock protein in the discrete brain regions of phencyclidine-treated rats. Brain Res. Mol. Brain Res. 73 (1999) 193-197
33. Noguchi K., Johnson R., and Ellison G. The effects of MK-801 on aspartate and glutamate levels in the anterior cingulate and retrosplenial cortices: an in vivo microdialysis study. Soc. Neurosci. Abstr. 24 (1998) 233
34. Olney J.W., and Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 52 (1995) 998-1007
35. Olney J.W., Wozniak D.F., and Farber N.B. Excitotoxic neurodegeneration in Alzheimer disease. New hypothesis and new therapeutic strategies. Arch. Neurol. 54 (1997) 1234-1240
36. Scruggs J.L., Patel S., Bubser M., and Deutch A.Y. DOI-induced activation of the cortex: dependence on 5-HT2A heteroreceptors on thalamocortical glutamatergic neurons. J. Neurosci. 20 (2000) 8846-8852
37. Serizawa A., Dando P.M., and Barretts A.J. Characterization of a mitochondrial metallopeptidase reveals neurolysin as a homologue of thimet oligopeptidase. J. Biol. Chem. 270 (1995) 2092-2098
38. Sharma T., and Mockler D. The cognitive efficacy of atypical antipsychotics in schizophrenia. J. Clin. Psychopharmacol. 18 suppl. 1 (1998) 12S-19S
39. Sharp F.R., Tomitaka M., Bernaudin M., and Tomitaka S. Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia?. Trends Neurosci. 24 (2001) 330-334
40. Shirayama Y., Mitsushio H., Takahashi K., and Nishikawa T. Differential effects of haloperidol on phencyclidine-induced reduction in substance P contents in rat brain regions. Synapse 35 (2000) 292-299
41. Shishido Y., Furushiro M., Tanabe S., Nishiyama S., Hashimoto S., Ohno M., Yamamoto T., and Watanabe S. ZTTA, a postproline cleaving enzyme inhibitor, improves cerebral ischemia-induced deficits in a three-panel runway task in rats. Pharmacol. Biochem. Behav. 55 (1996) 333-338
42. Shrimpton C.N., Glucksman M.J., Lew R.A., Tullai J.W., Margulies E.H., Roberts J.L., and Smith A.I. Thiol activation of endopeptidase EC 3.4.24.15: A novel mechanism for the regulation of the catalytic activity. J. Biol. Chem. 272 (1997) 17395-17399
43. Toide K., Okamiya K., Iwamoto Y., and Kato T. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on prolyl endopeptidase activity and substance P- and arginine-vasopressin-like immunoreactivity in the brains of aged rats. J. Neurochem. 65 (1995) 234-240
44. Ukai M., Shinkai N., Ohashai K., and Kameyama T. Substance P markedly ameliorates scopolamine-induced impairment of spontaneous alteration performance in the mouse. Brain Res. 673 (1995) 335-338
45. Waters S.M., and Davis T.P. Alterations of peptide metabolism and neuropeptidase activity in senile dementia of the Alzheimer's type. Ann. N.Y. Acad. Sci. 814 (1997) 30-39
46. Weis S., and Llenos I.C. GFAP-immunopositive astrocytes in schizophrenia. Schizophr. Res. 67 (2004) 293-295
47. Whitton P.S., Biggs C.S., Pearce B.R., and Fowler L.J. MK-801 increases extracellular 5-hydroxytryptamine in rat hippocampus and striatum in vivo. J. Neurochem. 58 (1992) 1573-1575
48. Yamamoto M., Chikuma T., and Kato T. Changes in the levels of neuropeptides and their metabolizing enzymes in the brain regions of nucleus basalis magnocellularis-lesioned rats. J. Pharmacol. Sci. 92 (2003) 400-410